Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Majority of sinus infections are reported to be caused by common cold and viral infections. These infections are classified as chronic and acute based on severity.
The chronic ones are those lasting for more than 3 months. Acute sinusitis get cured within 30 days.
At preliminary stage, sinus infections get diagnosed by physically inspecting characteristics of nasal mucosa, nasal septum’s structure, and presence of polyps.
At times, even imaging procedures like MRI (Magnetic Resonance Imaging), ultrasound, and CT (computed tomography) could be used to gauge the severity.
The commonly prescribed sinus therapeutic drugs include painkillers, corticosteroids, sulfonamides, antibiotics, and antihistamines.
The antibiotics used for treating bacterial infections herein include cephalospotin’s, penicillin, and macrolides.
Prednisone, triamcinolone, fluticasone, and mometastone are amongst the corticosteroids used to treat sinus infections. Sulfa drugs are inclusive of trimethoprim and sulfamethoxazole.
Antibiotics are expected to witness exponentiation in the forecast period. This could be attributed to diagnostic technologies being developed post introducing rapid microbial tests.
Besides, market players are looking for expansion in the markets of Asia-Pacific like Indonesia, Philippines, China, and India. This trend is expected to boost the market during the forecast period.
The other treatment options include bacterial lysates, capsaicin, anti-IL5, anti-IgE, and antifungals
The sinus therapeutic drugs market players are treading the innovative path followed by approvals to table their superiority. These measures are bound to give impetus to the market during the forecast period.
For instance –
Principal Consultant
The ongoing pandemic has compelled the sinus therapeutic drugs market players to speed up the production of drugs to address it, as it is a known fact that disorders in respiratory track can increase the risk of contraction.
For instance –
Since the last few months, Aviptaadil Covid-19 therapeutic has been treating critical Covid-19.
Traditionally, the US and Western European countries have remained the most lucrative markets for sinus therapeutic drug manufacturers. The scenario is likely to witness significant change during the forecast period, as many countries in Asia Pacific are offering lucrative opportunities.
The Asia Pacific sinus therapeutics drugs market is likely to grow at the fastest pace in the forecast period, as the players are expanding in this region, and some of them are also reported to shift their base over here.
Moreover, many countries in Asia Pacific have world’s worst air quality, and respiratory disorders have witnessed a rapid spike, with rise in industrialization.
The market players are launching new products to stand out as differentiators. This strategy is being emphasized on, and has kept the users guessing, regarding novelty.
For instance –
The major players in the sinus therapeutic drug market include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global sinus therapeutic drugs market is expected to witness a substantial CAGR of over 4% between 2022 and 2032. The onslaught of Covid-19 has resulted in increase in production of these drugs as it is directly related to disorders in the nasal tract.
The market players, though vying for innovation, should also think more from the inorganic growth perspective. As such, they should be looking forward to go for mergers, acquisitions, partnerships, joint ventures to be able to reach out to a broader audience.
Route of Administration
Distribution Channel
Disease Type
Geography
The sinus therapeutic drugs market is likely to secure a CAGR of 4% through 2032.
The sinus therapeutic drugs market size is estimated to cross US$ 6.35 Bn by 2032.
The sinus therapeutic drugs market is likely to record a value of US$ 4.29 Bn in 2022.
US is likely to lead the sinus therapeutic drugs market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Drug Development Trends 4. Key Success Factors 4.1. Adoption Analysis of Sinus Therapeutic Drugs 4.2. Regulatory Scenario 4.3. Reimbursement Scenario 4.4. Pipeline Analysis 4.5. Key Promotional Strategies, By Manufacturers 5. Sinus Therapeutic Drug Market Demand (Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030 5.1. Historical Market Value (US$ Mn) Analysis, 2015-2019 5.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.1.1. Global GDP Growth Outlook 6.1.2. Per Capita Healthcare Expenditure Outlook 6.2. Forecast Factors - Relevance & Impact 6.2.1. Growing Prevalence of Severe Allergic Asthma 6.2.2. Cost of Sinus Therapeutic Drug 6.2.3. Consolidation of Healthcare Industry 6.2.4. Increase in Patient Pool 6.3. Value Chain 6.4. Market Dynamics 6.4.1. Drivers 6.4.2. Restraints 6.4.3. Opportunity Analysis 6.5. COVID19 Crisis Analysis 6.5.1. Current COVID19 Statistics and Probable Future Impact 6.5.2. Current GDP Projection and Probable Impact 6.5.3. Current Economic Projection as compared to 2008 Economic analysis 6.5.4. COVID19 and Impact Analysis 6.5.4.1. Revenue By Drug Class 6.5.4.2. Revenue By Disease Type 6.5.4.3. Revenue By Route of Administration 6.5.4.4. Revenue By Distribution Channel 6.5.4.5. Revenue By Country 6.5.5. 2020 Market Scenario 6.5.6. Quarter by Quarter Forecast 6.5.7. Projected recovery Quarter 6.5.8. Recovery Scenario – Short term, Midterm and Long Term Impact 7. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) By Drug Class, 2015-2019 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020-2030 7.3.1. Аntіhіѕtаmіnеѕ 7.3.2. Аnаlgеѕісѕ 7.3.3. Ѕulрhоnаmіdеѕ 7.3.4. Соrtісоѕtеrоіdѕ 7.3.5. Аntіbіоtісѕ 7.3.6. NSAID’s 7.3.7. Оthеr Drug Сlаѕѕеѕ 7.4. Market Attractiveness Analysis By Drug Class 8. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Disease Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) By Disease Type, 2015-2019 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2020-2030 8.3.1. Асutе Sіnuѕіtіѕ 8.3.2. Ѕub-асutе Sіnuѕіtіѕ 8.3.3. Сhrоnіс Sіnuѕіtіѕ 8.4. Market Attractiveness Analysis By Disease Type 9. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2019 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2020-2030 9.3.1. Oral 9.3.2. Topical 9.3.3. Injectable 9.4. Market Attractiveness Analysis By Route of Administration 10. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015-2019 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020-2030 10.3.1. Ноѕріtаl Рhаrmасіеѕ 10.3.2. Rеtаіl Рhаrmасіе 10.3.3. Оnlіnе Рhаrmасіеѕ 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Drug Class 12.3.3. By Disease Type 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Latin America Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014 - 2018 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Drug Class 13.3.3. By Disease Type 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Europe Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy2020-2030 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug Class 14.3.3. By Disease Type 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. South Asia Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy2020-2030 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Drug Class 15.3.3. By Disease Type 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. East Asia Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug Class 16.3.3. By Disease Type 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Oceania Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Class 17.3.3. By Disease Type 17.3.4. By Route of Administration 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. By Drug Class 18.3.3. By Disease Type 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Key and Emerging Countries Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Sinus Therapeutic Drug Market Analysis 19.2.1. By Drug Class 19.2.2. By Disease Type 19.2.3. By Route of Administration 19.2.4. By Distribution Channel 19.3. Canada Sinus Therapeutic Drug Market Analysis 19.3.1. By Drug Class 19.3.2. By Disease Type 19.3.3. By Route of Administration 19.3.4. By Distribution Channel 19.4. Mexico Sinus Therapeutic Drug Market Analysis 19.4.1. By Drug Class 19.4.2. By Disease Type 19.4.3. By Route of Administration 19.4.4. By Distribution Channel 19.5. Brazil Sinus Therapeutic Drug Market Analysis 19.5.1. By Drug Class 19.5.2. By Disease Type 19.5.3. By Route of Administration 19.5.4. By Distribution Channel 19.6. U.K. Sinus Therapeutic Drug Market Analysis 19.6.1. By Drug Class 19.6.2. By Disease Type 19.6.3. By Route of Administration 19.6.4. By Distribution Channel 19.7. Germany Sinus Therapeutic Drug Market Analysis 19.7.1. By Drug Class 19.7.2. By Disease Type 19.7.3. By Route of Administration 19.7.4. By Distribution Channel 19.8. France Sinus Therapeutic Drug Market Analysis 19.8.1. By Drug Class 19.8.2. By Disease Type 19.8.3. By Route of Administration 19.8.4. By Distribution Channel 19.9. Italy Sinus Therapeutic Drug Market Analysis 19.9.1. By Drug Class 19.9.2. By Disease Type 19.9.3. By Route of Administration 19.9.4. By Distribution Channel 19.10. Spain Sinus Therapeutic Drug Market Analysis 19.10.1. By Drug Class 19.10.2. By Disease Type 19.10.3. By Route of Administration 19.10.4. By Distribution Channel 19.11. BENELUX Sinus Therapeutic Drug Market Analysis 19.11.1. By Drug Class 19.11.2. By Disease Type 19.11.3. By Route of Administration 19.11.4. By Distribution Channel 19.12. Russia Sinus Therapeutic Drug Market Analysis 19.12.1. By Drug Class 19.12.2. By Disease Type 19.12.3. By Route of Administration 19.12.4. By Distribution Channel 19.13. China Sinus Therapeutic Drug Market Analysis 19.13.1. By Drug Class 19.13.2. By Disease Type 19.13.3. By Route of Administration 19.13.4. By Distribution Channel 19.14. Japan Sinus Therapeutic Drug Market Analysis 19.14.1. By Drug Class 19.14.2. By Disease Type 19.14.3. By Route of Administration 19.14.4. By Distribution Channel 19.15. South Korea Sinus Therapeutic Drug Market Analysis 19.15.1. By Drug Class 19.15.2. By Disease Type 19.15.3. By Route of Administration 19.15.4. By Distribution Channel 19.16. India Sinus Therapeutic Drug Market Analysis 19.16.1. By Drug Class 19.16.2. By Disease Type 19.16.3. By Route of Administration 19.16.4. By Distribution Channel 19.17. Australia Sinus Therapeutic Drug Market Analysis 19.17.1. By Drug Class 19.17.2. By Disease Type 19.17.3. By Route of Administration 19.17.4. By Distribution Channel 19.18. New Zealand Sinus Therapeutic Drug Market Analysis 19.18.1. By Drug Class 19.18.2. By Disease Type 19.18.3. By Route of Administration 19.18.4. By Distribution Channel 19.19. GCC Countries Sinus Therapeutic Drug Market Analysis 19.19.1. By Drug Class 19.19.2. By Disease Type 19.19.3. By Route of Administration 19.19.4. By Distribution Channel 19.20. Turkey Sinus Therapeutic Drug Market Analysis 19.20.1. By Drug Class 19.20.2. By Disease Type 19.20.3. By Route of Administration 19.20.4. By Distribution Channel 19.21. South Africa Sinus Therapeutic Drug Market Analysis 19.21.1. By Drug Class 19.21.2. By Disease Type 19.21.3. By Route of Administration 19.21.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. By Regional footprint of Players 20.4.2. Product foot print by Players 20.4.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. AstraZeneca 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.1.5.1. Marketing Strategy 21.3.1.5.2. Product Strategy 21.3.1.5.3. Channel Strategy 21.3.2. Bausch Health 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.2.5.1. Marketing Strategy 21.3.2.5.2. Product Strategy 21.3.2.5.3. Channel Strategy 21.3.3. Nоvаrtіѕ АG 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.3.5.1. Marketing Strategy 21.3.3.5.2. Product Strategy 21.3.3.5.3. Channel Strategy 21.3.4. Ѕun Рhаrmасеutісаl Іnduѕtrіеѕ, Іnс 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.4.5.1. Marketing Strategy 21.3.4.5.2. Product Strategy 21.3.4.5.3. Channel Strategy 21.3.5. Rеddу'ѕ Lаbоrаtоrіеѕ, Іnс. 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.5.5.1. Marketing Strategy 21.3.5.5.2. Product Strategy 21.3.5.5.3. Channel Strategy 21.3.6. Теа Рhаrmасеutісаl Іnduѕtrіеѕ Ltd. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.6.5.1. Marketing Strategy 21.3.6.5.2. Product Strategy 21.3.6.5.3. Channel Strategy 21.3.7. Frеѕеnіuѕ Каbі UЅА 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.7.5.1. Marketing Strategy 21.3.7.5.2. Product Strategy 21.3.7.5.3. Channel Strategy 21.3.8. Јоhnѕоn & Јоhnѕоn 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.8.5.1. Marketing Strategy 21.3.8.5.2. Product Strategy 21.3.8.5.3. Channel Strategy 21.3.9. Рfіzеr Іnс 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.9.5.1. Marketing Strategy 21.3.9.5.2. Product Strategy 21.3.9.5.3. Channel Strategy 21.3.10. Јаnѕѕеn Рhаrmасеutісаlѕ, Іnс. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.10.5.1. Marketing Strategy 21.3.10.5.2. Product Strategy 21.3.10.5.3. Channel Strategy 21.3.11. GlaxoSmithKline plc 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.11.5.1. Marketing Strategy 21.3.11.5.2. Product Strategy 21.3.11.5.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Sinus Therapeutic Drugs Market
